These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415 [TBL] [Abstract][Full Text] [Related]
43. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. Ricci F; Bandello F; Navarra P; Staurenghi G; Stumpp M; Zarbin M Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153227 [TBL] [Abstract][Full Text] [Related]
44. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration. Brown GC; Brown MM; Rapuano S; Boyer D Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050 [TBL] [Abstract][Full Text] [Related]
45. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Yang S; Zhao J; Sun X Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279 [TBL] [Abstract][Full Text] [Related]
46. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Tolentino MJ Curr Mol Med; 2009 Nov; 9(8):973-81. PubMed ID: 19925410 [TBL] [Abstract][Full Text] [Related]
47. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Mitchell P Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685 [TBL] [Abstract][Full Text] [Related]
48. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Brown MM; Brown GC; Brown HC; Peet J Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724 [TBL] [Abstract][Full Text] [Related]
49. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Dixon JA; Oliver SC; Olson JL; Mandava N Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600 [TBL] [Abstract][Full Text] [Related]
50. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Stewart MW Mayo Clin Proc; 2012 Jan; 87(1):77-88. PubMed ID: 22212972 [TBL] [Abstract][Full Text] [Related]
54. [Role of VEGF in diseases of the retina]. Barquet LA Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044 [TBL] [Abstract][Full Text] [Related]
55. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Campa C; Harding SP Curr Drug Targets; 2011 Feb; 12(2):173-81. PubMed ID: 20887245 [TBL] [Abstract][Full Text] [Related]
56. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration. Feng L; Hu JH; Chen J; Xie X J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508 [TBL] [Abstract][Full Text] [Related]
57. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Batioğlu F; Astam N; Ozmert E Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852 [TBL] [Abstract][Full Text] [Related]